27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- Unicycive Therapeutics Inc (NASDAQ:UNCY) announced key findings of UNI-494 efficacy from a preclinical study in Geographic Atrophy (GA).
- UNI-494 is a mitochondrial potassium channel (mitochondrial KATP) activator in development for treating diseases affected by mitochondrial dysfunction, such as kidney, liver, and ocular diseases. Mitochondrial dysfunction is implicated in Age-related Macular Degeneration (AMD) progression.
- GA is an advanced form of AMD. The company evaluated the effect of UNI-494 in preventing visual function loss in a rat model of GA.
- The study evaluated four groups (n=8 per group): untreated, vehicle control, low dose of UNI-494, and high dose of UNI-494.
- Treatment of animals with the high dose of UNI-494 resulted in 150% and 200% improvement in contrast vision compared to vehicle and untreated animals.
- The company says it is on track to initiate a Phase I study in healthy volunteers during the first quarter of 2023 in the U.K. following clearance by the Medicines and Healthcare products Regulatory Agency.
- Price Action: UNCY shares are trading at $0.74 on the last check Monday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!